pp-075 Solution for injection/infusion

Indication: Pulmonary fibrosis, addressing chronic progressive scarring of lung tissue associated with dysregulated innate immune signaling. Clinical stage: Phase 2 Modality: Monoclonal antibody Mechanism / Target: Anti-TLR4 monoclonal antibody designed to inhibit innate immune activation pathways implicated in fibrotic remodeling, excessive extracellular matrix deposition, and inflammation-driven decline in pulmonary function. Route / form: Systemic administration (formulation not publicly specified). Differentiation: Aims to address upstream innate immune drivers of fibrosis rather than downstream inflammation or symptom pathways; represents a novel biologic approach that may complement or outperform current antifibrotic agents with limited efficacy.